ACT_for Alcohol Use Disorder and Depression

NCT ID: NCT06620276

Last Updated: 2025-12-22

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-05-01
• Study Completion Date: 2028-06-01

Brief Summary

Alcohol use disorders (AUDs) and depressive disorders frequently coexist, complicating the clinical management of patients suffering from them.

Taken separately, these two disorders have a significant prevalence in the population, and a recent meta-analysis concluded that coexistence could reach 1 in 5 patients (20.8%). This comorbidity represents a considerable challenge, particularly in cases of treatment-resistant depression (TRD), where patients do not respond to conventional pharmacological interventions.

Since alcohol can act as a powerful trigger for depressive symptoms, and conversely, a depressive state increases the risk of alcohol abuse, the question of intervention sequence is also of clinical interest: should priority be given to treating TRD, AUD or both simultaneously? This question raises a major issue for healthcare professionals, as current conventional therapeutic approaches present limitations in the concomitant management of these complex disorders.

Thus, in certain clinical settings, ketamine has emerged as a promising intervention to treat both TRD and AUD. In fact, ketamine has been shown to produce rapid but only transient antidepressant effects, and is part of the possible treatment arsenal for TRD. The potential of ketamine in the treatment of AUD has also been explored in recent studies, with a few small randomized controlled trials. In these trials, the combination of ketamine with psychotherapy, versus placebo, was investigated as a means of alleviating AUD. Ketamine was shown to increase abstinence rates, time to relapse and decrease the number of heavy drinking days.

Acceptance and Commitment Therapy (ACT) is a form of cognitive-behavioural therapy that emphasizes psychological flexibility and acceptance of difficult emotions and thoughts without judgment, a type of psychotherapy particularly relevant to AUD. Thus, adding ACT to ketamine treatment could increase the duration of ketamine's effect on depressive symptoms, while reducing AUD.

In view of this accumulated evidence of the potential benefit of ketamine and ACT, adding acceptance and commitment therapy to ketamine appears to be a promising option for improving outcomes in patients diagnosed with TRD comorbid with AUD. This study will not only verify the feasibility of this type of intervention in this particular patient population, but also the preliminary effects on their alcohol consumption and depressive symptoms.

Detailed Description

Study rationale Acceptance and Commitment Therapy (ACT) has been proposed as a particularly well-suited form of psychotherapy to be added to ketamine for improving its rapid but short antidepressant action. This is in part because of ketamine's acute effect on psychological flexibility, a crucial construct that is addressed with ACT.

There has been extensive efforts to find effective strategies to enhance and sustain the therapeutic response of ketamine, with most attempts using various pharmacotherapies-such as clonidine, D-cycloserine, lamotrigine, lithium, rapamycin, and riluzole- which have yielded mostly disappointing results. Consequently, the most common approach to extending ketamine benefits has been to administer repeated doses, although there is limited evidence supporting the long-term safety, efficacy, and practicality of this practice.

Substantial evidence indicates that psychotherapy can enhance the effects of pharmacological treatments, such as oral antidepressants, and even help maintain their benefits after discontinuation. While further research is required, it is plausible to assume that similar benefits of adding psychotherapy could extend to ketamine, particularly considering its potential neuroplastic effects.

In view of the accumulated evidence, the addition of ACT to a ketamine intervention appears as a promising option to improve the outcomes of patients diagnosed with AUD comorbid with TRD. This study will not only verify the feasibility of adding psychotherapy to ketamine in this population, but also the effect on their alcohol consumption and depressive symptoms.

Background Alcohol Use Disorder (AUD) and depressive disorders frequently coexist and complicate the clinical management and treatment outcomes for patients. It is estimated that around 1 in 10 people (10.4%) in the USA is experiencing a major depressive disorder (MDD) in the course of a year, while it goes up to 1 in 5 (20.6%) in the course of a lifetime. As for AUD, twelve month and lifetime prevalence are respectively 13.9% and 29.1%. When these disorders coexist, the prevalence is estimated as high as 20.8%, as reported by a recent meta-analysis. Research has also shown that individuals with AUD are approximately 2.3 times more likely to experience MDD within a given year.

This comorbidity presents a formidable challenge, particularly in cases of Treatment-Resistant Depression (TRD), a subset of MDD where patients do not respond to conventional pharmacological interventions. In the United States, it is estimated that out of 8.9 million adults receiving medication for MDD, 2.8 million, or 30.9%, are grappling with TRD. The economic impact is substantial, with the total annual cost of medication-treated MDD reaching $92.7 billion, nearly half of which-$43.8 billion or 47.2%-is attributable to TRD.

The concomitance of TRD and AUD represents a major clinical challenge as alcohol can act as a powerful trigger for depressive symptoms, and conversely a depressive state can increase the risk of alcohol abuse. This creates a complex, bidirectional relationship between the two disorders, considerably complicating the assessment and clinical management of these concurrent disorders. The question of intervention sequence is also of clinical interest: should treatment of TRD, AUD, or both simultaneously be prioritized? This question raises major challenges for health professionals, as current conventional therapeutic approaches present limitations in the concomitant management of these complex disorders. Traditional pharmacological treatments, such as antidepressants, may not be sufficiently effective or tolerated by some patients to treat these comorbid disorders. As for standard psychotherapeutic approaches, such as cognitive-behavioral therapy, the heterogeneity of symptoms and diversity of issues often mean that the needs of individuals suffering from these comorbidities cannot be met comprehensively.

In response to this challenge, in selected clinical settings, ketamine has emerged as a promising intervention for treating both AUD and depressive disorders. Ketamine, an NMDA receptor antagonist, has been shown to produce rapid and substantial, albeit short-lived (i.e. 7 days), antidepressant effects in individuals with TRD. Furthermore, ketamine potential in treating AUD has been explored in recent studies, with randomized controlled trials emerging. In such trials, the combination of ketamine to psychotherapy as compared to a placebo is studied to alleviate AUD. For instance, individuals with AUD who received a ketamine infusion and motivational therapy had improved rates of abstinence, prolonged time to relapse, and fewer days of heavy drinking than individuals with AUD who received an infusion of midazolam, considered as a placebo. Another team also compared the use of ketamine with a relapse prevention-based psychological therapy to placebo and found that there was a significant increase in the number of days abstinent from alcohol.

Considering the substantial but transient effect of ketamine on depressive symptomatology, and its promising results in AUD patients, a novel approach is to add a psychotherapeutic component to the ketamine treatment with the aim of enhancing and prolonging its effect. Acceptance and Commitment Therapy (ACT) seems to be a particularly well-suited form of psychotherapy to be added to ketamine treatment. Indeed, ACT is a form of cognitive-behavioural therapy that emphasizes psychological flexibility and the acceptance of difficult emotions and thoughts without judgment. ACT has been extensively studied in various psychopathologies, including anxiety and depression, demonstrating positive outcomes in multiple rigorous clinical trials and meta-analysis. Growing evidence suggest that ACT may be an effective and even superior treatment for individuals with substance use disorders ACT encourages individuals to commit to behavior changes consistent with their values, which can be particularly beneficial for those with AUD and comorbid TRD. Ketamine has been shown to have an acute effect on psychological flexibility, and the addition of ACT's focus on acceptance and value-driven behavior holds promise for improving the ketamine's rapid and short antidepressant action and addressing the complex interplay of AUD and TRD.

Standard treatment options

Alcohol Use Disorder (AUD):

In 2023, a committee of AUD specialists published the Canadian guideline with treatment recommendations for AUD. As a strong recommendation, they first proposed that all patients with AUD should be offered specialist-led psychosocial treatment interventions, such as cognitive behavioral therapy or family-based therapy. However, both therapies were found to have small to medium beneficial impacts on AUD outcomes. For pharmacotherapy, as a complement to the psychosocial treatment, naltrexone or acamprosate were recommended as first-line therapy. Second-line options, some of them being used as off-label therapies, were also proposed, namely gabapentin, topiramate and disulfiram. Of note, these recommendations are in line with other reviews of AUD pharmacotherapy and other national guidelines (namely American and Australian guidelines).

However, there are some limitations associated with the use of those treatment options. Apart from safety concerns, with common AE associated with treatments (nausea, dizziness and fatigue, among others), there is an ongoing debate among experts about the actual efficacy of the treatment options. In fact, naltrexone and acamprosate have an estimated number needed to treat to prevent a return to heavy drinking of 12, with modest differences found when comparing drugs with placebo, contributing to their underutilization in AUD patients. For instance, in over 28,000 Medicare beneficiaries hospitalized with a primary or secondary diagnosis of AUD, it was found that only 0.7% of patients started pharmacotherapy within two days after discharge and 1.3% within 30 days. Even among patients for whom AUD was the primary diagnosis after hospitalization, only 2.3% started pharmacotherapy within two days of discharge.

Treatment Resistant Depression (TRD):

Leading experts in TRD summarized in 2023 the options available to try and reach a favorable outcome in individuals who fail to respond to at least two adequate trials of psychotropics against depression. First, extending a current antidepressant trial could be a potential treatment plan. A systematic review determined that up to 20% of patients who did not respond to their antidepressant in the first four weeks of treatment responded during the following four weeks (from weeks five to eight), and up to 10% during weeks nine to twelve. Similarly, there is some evidence, albeit conflicting, that switching antidepressants or combining antidepressants could benefit some patients, especially if the change or addition involves a new mechanism of action. To cite only one example of this option, adding antidepressants with antagonism activity on the alpha-2 receptor (i.e., mirtazapine, trazodone) to a selective serotonin reuptake inhibitor was superior to monotherapy in a meta-analysis.

Other treatment modalities have also been studied, including adding various pharmacological agents like second-generation antipsychotics and mood stabilizers. In real-world settings, most patients with TRD are prescribed multiple psychotropic medications, often for extended periods, with generally limited success. For example, a recent cohort study conducted over 12 months across various European countries, involving 411 patients with TRD, highlighted high rates of polypharmacy alongside modest clinical improvement-only about 30% showed a positive response after 6 to 12 months of consistent treatment. The study also indicated a concerning level of therapeutic inertia, where 60% of patients did not undergo any changes in their treatment plan, despite ongoing poor outcomes.

Electroconvulsive therapy (ECT), aside from the usual pharmacological approaches, is considered one of the most empirically supported interventions for TRD. However, despite its effectiveness, ECT is often hindered by significant barriers, including societal stigma, inconsistent access, and notable side effects such as memory loss, largely due to the need for general anesthesia during the procedure.

Amid the current treatment challenges, the rapid and robust antidepressant effects of subanesthetic doses of IV racemic ketamine-a distinctive N-methyl-D-aspartate (NMDA) receptor antagonist-have sparked considerable interest and optimism. Meta-analyses suggest that nearly half of patients with treatment-resistant depression (TRD) experience a significant reduction in depressive symptoms (over 50%) within just hours to days following a single 40-minute IV ketamine infusion. This promising efficacy has led many experts to regard subanesthetic ketamine as one of the most transformative advancements in psychiatric pharmacology in recent decades. While impressive, ketamine's benefits typically fade within days or weeks.

Given the evidence of ketamine's beneficial effect, the neuromodulation service of the CHUM began providing this treatment to patients with TRD in 2018, covering the whole province of Quebec. Since then, the neuromodulation service has created a state-of-the-art infrastructure for the ketamine service.

Conditions

Depression - Major Depressive Disorder; Alcohol Use Disorder

Keywords

Depression; Psychotherapy; Alcohol Use Disorder; Ketamine-assisted Acceptance and Commitment Therapy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Ketamine-assisted Acceptance and Commitment Therapy

30 consecutive participants who will receive 6 infusions of ketamine and 8 sessions of Acceptance and Commitment Therapy (ACT) at our research site.

Group Type: EXPERIMENTAL

Acceptance and Commitment Therapy

Intervention Type: BEHAVIORAL

The ACT intervention consists of eight weekly 50 minute sessions, delivered in person when possible, with virtual options available. ACT targets psychological flexibility by addressing fusion, evaluation, avoidance, and reason giving through six core processes: acceptance, values, committed action, present moment awareness, cognitive defusion, and self as context. Sessions combine didactic content and experiential exercises following a standardized manual, with therapists trained in ACT. Participants receive a workbook to support practice. Each session begins with a brief mindfulness exercise that evolves across weeks, starting with grounding and simple emotional labeling, then progressing to neutral sensory descriptions and openness to challenging sensations.

Ketamine

Intervention Type: DRUG

The protocol includes 6 IV ketamine infusions over 4 weeks at the CHUM Neuromodulation Unit, following the Montreal Model integrating psychotherapeutic and contextual elements (e.g. preparation, music, and integration).

Infusions occur twice weekly in weeks 3 and 4 of the treatment protocol, then once weekly in weeks 5 and 6. The first dose is 0.5 mg/kg in 250 mL saline over 40 minutes, with possible titration up to 1.0 mg/kg based on tolerability, clinical response, and participant preferences. Blood alcohol level is measured by breathalyzer before each session, and if any detectable alcohol is present (i.e., BAC ≠ 0%), the infusion will be postponed and rescheduled.

Infusions occur in a quiet, dim room with continuous monitoring. Before each infusion, a brief mindfulness exercise promotes openness to internal experience. During the infusion, participants listen to a curated 60 minute instrumental playlist to support emotional exploration.

Interventions

Acceptance and Commitment Therapy

The ACT intervention consists of eight weekly 50 minute sessions, delivered in person when possible, with virtual options available. ACT targets psychological flexibility by addressing fusion, evaluation, avoidance, and reason giving through six core processes: acceptance, values, committed action, present moment awareness, cognitive defusion, and self as context. Sessions combine didactic content and experiential exercises following a standardized manual, with therapists trained in ACT. Participants receive a workbook to support practice. Each session begins with a brief mindfulness exercise that evolves across weeks, starting with grounding and simple emotional labeling, then progressing to neutral sensory descriptions and openness to challenging sensations.

Intervention Type: BEHAVIORAL

Ketamine

The protocol includes 6 IV ketamine infusions over 4 weeks at the CHUM Neuromodulation Unit, following the Montreal Model integrating psychotherapeutic and contextual elements (e.g. preparation, music, and integration).

Infusions occur twice weekly in weeks 3 and 4 of the treatment protocol, then once weekly in weeks 5 and 6. The first dose is 0.5 mg/kg in 250 mL saline over 40 minutes, with possible titration up to 1.0 mg/kg based on tolerability, clinical response, and participant preferences. Blood alcohol level is measured by breathalyzer before each session, and if any detectable alcohol is present (i.e., BAC ≠ 0%), the infusion will be postponed and rescheduled.

Infusions occur in a quiet, dim room with continuous monitoring. Before each infusion, a brief mindfulness exercise promotes openness to internal experience. During the infusion, participants listen to a curated 60 minute instrumental playlist to support emotional exploration.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Provision of written informed consent after reading and understanding the patient information handout
• Alcohol Use Disorder (AUD) diagnosed by a trained psychiatrist
• Diagnosis of treatment resistant unipolar or bipolar depression, defined as failure to respond to ≥2 adequate trials per Canadian national depression guidelines
• Willingness to engage in 8 weekly psychotherapy sessions
• No changes to psychotropic medications during treatment
• Average daily ethanol consumption of at least moderate risk as per WHO risk levels (Men: >40 to 60 g per day or >2.9 to 4.3 drinks / Women: >20 to 40 g per day or >1.4 to 2.9 drinks)
• Bipolar or unipolar depressive episode (DSM5), current episode, with MADRS ≥ 20
• Age 18 to 70 years
• Agreement to abstain from consuming grapefruit juice on ketamine infusion days
• Agreement to abstain from driving or operating heavy machinery after infusions until the next day

Exclusion Criteria

• Current participation in other evidence based psychotherapeutic interventions for mood disorders or substance abuse
• Inability to commit to the study protocol due to professional or personal obligations
• Non English or non French speaking
• Psychiatric comorbidity likely to take precedence over AUD or TRD
• Acute psychotic disorder or acute psychotic symptoms
• Current or prior substance abuse or dependence other than AUD (except caffeine or nicotine)
• Non response to esketamine or ketamine during the current depressive episode
• Known intellectual disability or autism spectrum disorder
• Inability to attend regular visits to the CHUM Neuromodulation clinic
• Depression secondary to stroke, cancer, or severe medical conditions
• Risk factors for intracranial hemorrhage (trauma, aneurysm, neurosurgery)
• Uncontrolled hypertension or significant coronary or cerebrovascular disease
• Renal or hepatic impairment
• Pregnant, lactating, or of childbearing potential without approved contraception use during ketamine treatment, with a negative urine pregnancy test required at baseline
• Abnormal liver function tests (AST or ALT ≥ 3 times upper normal limit)
• Clinically significant abnormal ECG results
• Unstable thyroid hormone levels or uncorrected hypo or hyper thyroidism
• Any unstable or clinically significant condition judged by the study physician to interfere with treatment
• Positive toxicology screen for drugs not prescribed
• Unwillingness to abstain from benzodiazepines, narcotics, or NMDA antagonists (including memantine and lamotrigine) 12 hours before infusions
• Known intolerance or hypersensitivity to ketamine
• Significant hearing impairment not improved by aids
• Any recent significant decline in exercise tolerance

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nicolas Garel, MD MSc

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier d'Université de Montréal

Locations

Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Nicolas Garel, MD MSc

Role: CONTACT

Phone: 514-890-8000

Email: nicolas.garel.med@ssss.gouv.qc.ca

Samuel Cyr, PhD

Role: CONTACT

Phone: 514-890-8000

Email: samuel.cyr.chum@ssss.gouv.qc.ca

Facility Contacts

Nicolas Garel, MD MSc

Role: primary

Samuel Cyr, PhD

Role: backup

References

Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995 Feb;19(1):92-9. doi: 10.1111/j.1530-0277.1995.tb01475.x.

Reference Type: BACKGROUND

PMID: 7771669 (View on PubMed)

Anton RF, Moak DH, Latham PK. The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry. 1996 Mar;53(3):225-31. doi: 10.1001/archpsyc.1996.01830030047008.

Reference Type: BACKGROUND

PMID: 8611059 (View on PubMed)

Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, Sheehan JJ. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. J Clin Psychiatry. 2021 Mar 16;82(2):20m13699. doi: 10.4088/JCP.20m13699.

Reference Type: BACKGROUND

PMID: 33989464 (View on PubMed)

Wood E, Bright J, Hsu K, Goel N, Ross JWG, Hanson A, Teed R, Poulin G, Denning B, Corace K, Chase C, Halpape K, Lim R, Kealey T, Rehm J; Canadian Alcohol Use Disorder Guideline Committee. Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder. CMAJ. 2023 Oct 16;195(40):E1364-E1379. doi: 10.1503/cmaj.230715.

Reference Type: BACKGROUND

PMID: 37844924 (View on PubMed)

Wolff M, Evens R, Mertens LJ, Koslowski M, Betzler F, Grunder G, Jungaberle H. Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance. Front Psychiatry. 2020 Feb 21;11:5. doi: 10.3389/fpsyt.2020.00005. eCollection 2020.

Reference Type: BACKGROUND

PMID: 32153433 (View on PubMed)

Wilkinson ST, Kitay BM, Harper A, Rhee TG, Sint K, Ghosh A, Lopez MO, Saenz S, Tsai J. Barriers to the Implementation of Electroconvulsive Therapy (ECT): Results From a Nationwide Survey of ECT Practitioners. Psychiatr Serv. 2021 Jul 1;72(7):752-757. doi: 10.1176/appi.ps.202000387. Epub 2021 May 11.

Reference Type: BACKGROUND

PMID: 33971727 (View on PubMed)

Wikberg C, Nejati S, Larsson ME, Petersson EL, Westman J, Ariai N, Kivi M, Eriksson M, Eggertsen R, Hange D, Baigi A, Bjorkelund C. Comparison Between the Montgomery-Asberg Depression Rating Scale-Self and the Beck Depression Inventory II in Primary Care. Prim Care Companion CNS Disord. 2015 Jun 25;17(3):10.4088/PCC.14m01758. doi: 10.4088/PCC.14m01758. eCollection 2015.

Reference Type: BACKGROUND

PMID: 26644958 (View on PubMed)

Walsh Z, Thiessen MS. Psychedelics and the new behaviourism: considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy. Int Rev Psychiatry. 2018 Aug;30(4):343-349. doi: 10.1080/09540261.2018.1474088. Epub 2018 Sep 25.

Reference Type: BACKGROUND

PMID: 30251904 (View on PubMed)

Ustun TB, Chatterji S, Kostanjsek N, Rehm J, Kennedy C, Epping-Jordan J, Saxena S, von Korff M, Pull C; WHO/NIH Joint Project. Developing the World Health Organization Disability Assessment Schedule 2.0. Bull World Health Organ. 2010 Nov 1;88(11):815-23. doi: 10.2471/BLT.09.067231. Epub 2010 May 20.

Reference Type: BACKGROUND

PMID: 21076562 (View on PubMed)

Teresi JA, Yu X, Stewart AL, Hays RD. Guidelines for Designing and Evaluating Feasibility Pilot Studies. Med Care. 2022 Jan 1;60(1):95-103. doi: 10.1097/MLR.0000000000001664.

Reference Type: BACKGROUND

PMID: 34812790 (View on PubMed)

Stubbs KR, Van Bezooyen J, Tang Y-l. Chapter 31 - Managing treatment-resistant depression with comorbid substance use disorders. In: Quevedo J, Riva-Posse P, Bobo WV, editors. Managing Treatment-Resistant Depression: Academic Press; 2022. p. 461-72.

Reference Type: BACKGROUND

Strauss B, Gawlytta R, Schleu A, Frenzl D. Negative effects of psychotherapy: estimating the prevalence in a random national sample. BJPsych Open. 2021;7(6):e186.

Reference Type: BACKGROUND

Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092.

Reference Type: BACKGROUND

PMID: 16717171 (View on PubMed)

Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Mendlewicz J; Group for the Study of Resistant Depression. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007 Jul;68(7):1062-70. doi: 10.4088/jcp.v68n0713.

Reference Type: BACKGROUND

PMID: 17685743 (View on PubMed)

Sobell LC, Sobell MB. Timeline Follow-Back. In: Litten RZ, Allen JP, editors. Measuring Alcohol Consumption. Totowa, NJ: Humana Press; 1992. p. 41-72.

Reference Type: BACKGROUND

Smout MF, Longo M, Harrison S, Minniti R, Wickes W, White JM. Psychosocial treatment for methamphetamine use disorders: a preliminary randomized controlled trial of cognitive behavior therapy and Acceptance and Commitment Therapy. Subst Abus. 2010 Apr;31(2):98-107. doi: 10.1080/08897071003641578.

Reference Type: BACKGROUND

PMID: 20408061 (View on PubMed)

Smith-Apeldoorn SY, Veraart JK, Spijker J, Kamphuis J, Schoevers RA. Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. Lancet Psychiatry. 2022 Nov;9(11):907-921. doi: 10.1016/S2215-0366(22)00317-0.

Reference Type: BACKGROUND

PMID: 36244360 (View on PubMed)

Sloshower J, Guss J, Krause R, Wallace RM, Williams MT, Reed S, et al. Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame. Journal of Contextual Behavioral Science. 2020;15:12-9.

Reference Type: BACKGROUND

Singleton EG, Gorelick DA. Mechanisms of alcohol craving and their clinical implications. Recent Dev Alcohol. 1998;14:177-95. doi: 10.1007/0-306-47148-5_8.

Reference Type: BACKGROUND

PMID: 9751946 (View on PubMed)

Singleton E, Tiffany S, Henningfield J. Development and validation of a new questionnaire to assess craving for alcohol. NIDA Research Monograph. 1995;153:289-.

Reference Type: BACKGROUND

Shallcross A, Lu NY, Hays RD. Evaluation of the Psychometric Properties of the Five Facet of Mindfulness Questionnaire. J Psychopathol Behav Assess. 2020 Jun;42(2):271-280. doi: 10.1007/s10862-019-09776-5. Epub 2020 Jan 10.

Reference Type: BACKGROUND

PMID: 32655208 (View on PubMed)

Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993 Jun;88(6):791-804. doi: 10.1111/j.1360-0443.1993.tb02093.x.

Reference Type: BACKGROUND

PMID: 8329970 (View on PubMed)

Saunders JB, Aasland OG, Amundsen A, Grant M. Alcohol consumption and related problems among primary health care patients: WHO collaborative project on early detection of persons with harmful alcohol consumption--I. Addiction. 1993 Mar;88(3):349-62. doi: 10.1111/j.1360-0443.1993.tb00822.x.

Reference Type: BACKGROUND

PMID: 8461852 (View on PubMed)

Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000 Aug;23(4):334-40. doi: 10.1002/1098-240x(200008)23:43.0.co;2-g.

Reference Type: BACKGROUND

PMID: 10940958 (View on PubMed)

Salani D, Goldin D, Valdes B, DeSantis J. Electroconvulsive Therapy for Treatment-Resistant Depression: Dispelling the Stigma. J Psychosoc Nurs Ment Health Serv. 2023 Jun;61(6):11-17. doi: 10.3928/02793695-20230222-02. Epub 2023 Mar 5.

Reference Type: BACKGROUND

PMID: 36853035 (View on PubMed)

Sackeim HA. Modern Electroconvulsive Therapy: Vastly Improved yet Greatly Underused. JAMA Psychiatry. 2017 Aug 1;74(8):779-780. doi: 10.1001/jamapsychiatry.2017.1670. No abstract available.

Reference Type: BACKGROUND

PMID: 28658461 (View on PubMed)

Rothberg RL, Azhari N, Haug NA, Dakwar E. Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. J Psychopharmacol. 2021 Feb;35(2):150-158. doi: 10.1177/0269881120970879. Epub 2020 Dec 13.

Reference Type: BACKGROUND

PMID: 33307947 (View on PubMed)

Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. J Psychopharmacol. 2019 Sep;33(9):1076-1087. doi: 10.1177/0269881119855974. Epub 2019 Jul 11.

Reference Type: BACKGROUND

PMID: 31294673 (View on PubMed)

Petersen TJ. Enhancing the efficacy of antidepressants with psychotherapy. J Psychopharmacol. 2006 May;20(3 Suppl):19-28. doi: 10.1177/1359786806064314.

Reference Type: BACKGROUND

PMID: 16644768 (View on PubMed)

Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007 Dec 1;62(11):1217-27. doi: 10.1016/j.biopsych.2007.03.027. Epub 2007 Jun 22.

Reference Type: BACKGROUND

PMID: 17588546 (View on PubMed)

Papakostas GI. Maintaining Rapid Antidepressant Effects Following Ketamine Infusion: A Major Unmet Need. J Clin Psychiatry. 2020 Feb 4;81(2):19r12859. doi: 10.4088/JCP.19r12859.

Reference Type: BACKGROUND

PMID: 32023369 (View on PubMed)

Pahnke WN. Psychedelic drugs and mystical experience. Int Psychiatry Clin. 1969;5(4):149-62. No abstract available.

Reference Type: BACKGROUND

PMID: 4892137 (View on PubMed)

Pahnke WN. Drugs and Mysticism: An Analysis of the Relationship Between Psychedelic Drugs and the Mystical Consciousness : a Thesis: Harvard University; 1963.

Reference Type: BACKGROUND

Osaji J, Ojimba C, Ahmed S. The Use of Acceptance and Commitment Therapy in Substance Use Disorders: A Review of Literature. J Clin Med Res. 2020 Oct;12(10):629-633. doi: 10.14740/jocmr4311. Epub 2020 Sep 21.

Reference Type: BACKGROUND

PMID: 33029268 (View on PubMed)

Oliveira-Maia AJ, Bobrowska A, Constant E, Ito T, Kambarov Y, Luedke H, Mulhern-Haughey S, von Holt C. Treatment-Resistant Depression in Real-World Clinical Practice: A Systematic Literature Review of Data from 2012 to 2022. Adv Ther. 2024 Jan;41(1):34-64. doi: 10.1007/s12325-023-02700-0. Epub 2023 Oct 26.

Reference Type: BACKGROUND

PMID: 37882883 (View on PubMed)

Nikolin S, Rodgers A, Schwaab A, Bahji A, Zarate C Jr, Vazquez G, Loo C. Ketamine for the treatment of major depression: a systematic review and meta-analysis. EClinicalMedicine. 2023 Aug 3;62:102127. doi: 10.1016/j.eclinm.2023.102127. eCollection 2023 Aug.

Reference Type: BACKGROUND

PMID: 37593223 (View on PubMed)

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9. doi: 10.1192/bjp.134.4.382.

Reference Type: BACKGROUND

PMID: 444788 (View on PubMed)

Mollaahmetoglu OM, Keeler J, Ashbullby KJ, Ketzitzidou-Argyri E, Grabski M, Morgan CJA. "This Is Something That Changed My Life": A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders. Front Psychiatry. 2021 Aug 16;12:695335. doi: 10.3389/fpsyt.2021.695335. eCollection 2021.

Reference Type: BACKGROUND

PMID: 34483991 (View on PubMed)

Meis LA, Griffin JM, Greer N, Jensen AC, Macdonald R, Carlyle M, Rutks I, Wilt TJ. Couple and family involvement in adult mental health treatment: a systematic review. Clin Psychol Rev. 2013 Mar;33(2):275-86. doi: 10.1016/j.cpr.2012.12.003. Epub 2012 Dec 22.

Reference Type: BACKGROUND

PMID: 23321286 (View on PubMed)

McPheeters M, O'Connor EA, Riley S, Kennedy SM, Voisin C, Kuznacic K, Coffey CP, Edlund MD, Bobashev G, Jonas DE. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA. 2023 Nov 7;330(17):1653-1665. doi: 10.1001/jama.2023.19761.

Reference Type: BACKGROUND

PMID: 37934220 (View on PubMed)

McMullen EP, Lee Y, Lipsitz O, Lui LMW, Vinberg M, Ho R, Rodrigues NB, Rosenblat JD, Cao B, Gill H, Teopiz KM, Cha DS, McIntyre RS. Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression. Adv Ther. 2021 Jun;38(6):2795-2820. doi: 10.1007/s12325-021-01732-8. Epub 2021 Apr 30.

Reference Type: BACKGROUND

PMID: 33929660 (View on PubMed)

McKiernan P, Cloud R, Patterson DA, Wolf Adelv Unegv Waya S, Golder S, Besel K. Development of a Brief Abstinence Self-Efficacy Measure. J Soc Work Pract Addict. 2011 Jul;11(3):245-253. doi: 10.1080/1533256X.2011.593445. Epub 2011 Aug 16.

Reference Type: BACKGROUND

PMID: 23559892 (View on PubMed)

McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, Gorwood P, Ho R, Kasper S, Kennedy SH, Ly-Uson J, Mansur RB, McAllister-Williams RH, Murrough JW, Nemeroff CB, Nierenberg AA, Rosenblat JD, Sanacora G, Schatzberg AF, Shelton R, Stahl SM, Trivedi MH, Vieta E, Vinberg M, Williams N, Young AH, Maj M. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023 Oct;22(3):394-412. doi: 10.1002/wps.21120.

Reference Type: BACKGROUND

PMID: 37713549 (View on PubMed)

McHugh RK, Weiss RD. Alcohol Use Disorder and Depressive Disorders. Alcohol Res. 2019 Jan 1;40(1):arcr.v40.1.01. doi: 10.35946/arcr.v40.1.01. eCollection 2019 Oct 21.

Reference Type: BACKGROUND

PMID: 31649834 (View on PubMed)

Mathai DS, Mora V, Garcia-Romeu A. Toward Synergies of Ketamine and Psychotherapy. Front Psychol. 2022 Mar 25;13:868103. doi: 10.3389/fpsyg.2022.868103. eCollection 2022.

Reference Type: BACKGROUND

PMID: 35401323 (View on PubMed)

Marini C, Northover NS, Gold ND, Rogers UK, O'Donnell KC, Tofighi B, Ross S, Bogenschutz MP. A Systematic Approach to Standardizing Drinking Outcomes From Timeline Followback Data. Subst Abuse. 2023 Mar 11;17:11782218231157558. doi: 10.1177/11782218231157558. eCollection 2023.

Reference Type: BACKGROUND

PMID: 36923069 (View on PubMed)

Magill M, Ray L, Kiluk B, Hoadley A, Bernstein M, Tonigan JS, Carroll K. A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition. J Consult Clin Psychol. 2019 Dec;87(12):1093-1105. doi: 10.1037/ccp0000447. Epub 2019 Oct 10.

Reference Type: BACKGROUND

PMID: 31599606 (View on PubMed)

MacLeod MA, Tremblay PF, Graham K, Bernards S, Rehm J, Wells S. Psychometric properties and a latent class analysis of the 12-item World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) in a pooled dataset of community samples. Int J Methods Psychiatr Res. 2016 Dec;25(4):243-254. doi: 10.1002/mpr.1523. Epub 2016 Sep 15.

Reference Type: BACKGROUND

PMID: 27634553 (View on PubMed)

Maclean KA, Leoutsakos JM, Johnson MW, Griffiths RR. Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin. J Sci Study Relig. 2012 Dec;51(4):721-737. doi: 10.1111/j.1468-5906.2012.01685.x.

Reference Type: BACKGROUND

PMID: 23316089 (View on PubMed)

Lee EB, An W, Levin ME, Twohig MP. An initial meta-analysis of Acceptance and Commitment Therapy for treating substance use disorders. Drug Alcohol Depend. 2015 Oct 1;155:1-7. doi: 10.1016/j.drugalcdep.2015.08.004. Epub 2015 Aug 13.

Reference Type: BACKGROUND

PMID: 26298552 (View on PubMed)

Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron. 2019 Mar 6;101(5):774-778. doi: 10.1016/j.neuron.2019.02.005.

Reference Type: BACKGROUND

PMID: 30844397 (View on PubMed)

Kryst J, Kawalec P, Mitoraj AM, Pilc A, Lason W, Brzostek T. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol Rep. 2020 Jun;72(3):543-562. doi: 10.1007/s43440-020-00097-z. Epub 2020 Apr 16.

Reference Type: BACKGROUND

PMID: 32301056 (View on PubMed)

Kranzler HR, Soyka M. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review. JAMA. 2018 Aug 28;320(8):815-824. doi: 10.1001/jama.2018.11406.

Reference Type: BACKGROUND

PMID: 30167705 (View on PubMed)

Koob GF. Alcohol Use Disorder Treatment: Problems and Solutions. Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:255-275. doi: 10.1146/annurev-pharmtox-031323-115847.

Reference Type: BACKGROUND

PMID: 38261428 (View on PubMed)

Klein JP, Rozental A, Surig S, Moritz S. Adverse Events of Psychological Interventions: Definitions, Assessment, Current State of the Research and Implications for Research and Clinical Practice. Psychother Psychosom. 2024;93(5):308-315. doi: 10.1159/000540212. Epub 2024 Jul 29.

Reference Type: BACKGROUND

PMID: 39074446 (View on PubMed)

Klatte R, Strauss B, Fluckiger C, Rosendahl J. Adverse events in psychotherapy randomized controlled trials: A systematic review. Psychother Res. 2025 Jan;35(1):84-99. doi: 10.1080/10503307.2023.2286992. Epub 2023 Dec 13.

Reference Type: BACKGROUND

PMID: 38090772 (View on PubMed)

Kang MJY, Hawken E, Vazquez GH. The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity. Front Psychiatry. 2022 Apr 25;13:860882. doi: 10.3389/fpsyt.2022.860882. eCollection 2022.

Reference Type: BACKGROUND

PMID: 35546951 (View on PubMed)

Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, Garbutt JC. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014 May 14;311(18):1889-900. doi: 10.1001/jama.2014.3628.

Reference Type: BACKGROUND

PMID: 24825644 (View on PubMed)

Jimenez M, Grana JL, Montes V, Rubio G. Alcohol craving scale based on three factors. Eur Addict Res. 2009;15(3):135-42. doi: 10.1159/000210043. Epub 2009 Mar 31.

Reference Type: BACKGROUND

PMID: 19332992 (View on PubMed)

Hunt GE, Malhi GS, Lai HMX, Cleary M. Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990-2019: Systematic review and meta-analysis. J Affect Disord. 2020 Apr 1;266:288-304. doi: 10.1016/j.jad.2020.01.141. Epub 2020 Jan 26.

Reference Type: BACKGROUND

PMID: 32056890 (View on PubMed)

Hoeppner BB, Stout RL, Jackson KM, Barnett NP. How good is fine-grained Timeline Follow-back data? Comparing 30-day TLFB and repeated 7-day TLFB alcohol consumption reports on the person and daily level. Addict Behav. 2010 Dec;35(12):1138-43. doi: 10.1016/j.addbeh.2010.08.013. Epub 2010 Aug 13.

Reference Type: BACKGROUND

PMID: 20822852 (View on PubMed)

Higgins-Biddle JC, Babor TF. A review of the Alcohol Use Disorders Identification Test (AUDIT), AUDIT-C, and USAUDIT for screening in the United States: Past issues and future directions. Am J Drug Alcohol Abuse. 2018;44(6):578-586. doi: 10.1080/00952990.2018.1456545. Epub 2018 May 3.

Reference Type: BACKGROUND

PMID: 29723083 (View on PubMed)

Hermida AP, Glass OM, Shafi H, McDonald WM. Electroconvulsive Therapy in Depression: Current Practice and Future Direction. Psychiatr Clin North Am. 2018 Sep;41(3):341-353. doi: 10.1016/j.psc.2018.04.001. Epub 2018 Jun 15.

Reference Type: BACKGROUND

PMID: 30098649 (View on PubMed)

Henssler J, Kurschus M, Franklin J, Bschor T, Baethge C. Trajectories of Acute Antidepressant Efficacy: How Long to Wait for Response? A Systematic Review and Meta-Analysis of Long-Term, Placebo-Controlled Acute Treatment Trials. J Clin Psychiatry. 2018 May/Jun;79(3):17r11470. doi: 10.4088/JCP.17r11470.

Reference Type: BACKGROUND

PMID: 29659207 (View on PubMed)

Henssler J, Alexander D, Schwarzer G, Bschor T, Baethge C. Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022 Apr 1;79(4):300-312. doi: 10.1001/jamapsychiatry.2021.4313.

Reference Type: BACKGROUND

PMID: 35171215 (View on PubMed)

Heerlein K, Perugi G, Otte C, Frodl T, Degraeve G, Hagedoorn W, Oliveira-Maia AJ, Perez Sola V, Rathod S, Rosso G, Sierra P, Malynn S, Morrens J, Verrijcken C, Gonzalez B, Young AH. Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes. J Affect Disord. 2021 Jul 1;290:334-344. doi: 10.1016/j.jad.2021.03.073. Epub 2021 Apr 1.

Reference Type: BACKGROUND

PMID: 34044256 (View on PubMed)

Hayes SC, Wilson KG, Gifford EV, Bissett R, Piasecki M, Batten SV, et al. A Preliminary trial of twelve-step facilitation and acceptance and commitment therapy with polysubstance-abusing methadone-maintained opiate addicts. Behavior Therapy. 2004;35(4):667-88.

Reference Type: BACKGROUND

Hasin DS, Wall M, Witkiewitz K, Kranzler HR, Falk D, Litten R, Mann K, O'Malley SS, Scodes J, Robinson RL, Anton R; Alcohol Clinical Trials Initiative (ACTIVE) Workgroup. Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. Lancet Psychiatry. 2017 Jun;4(6):469-476. doi: 10.1016/S2215-0366(17)30130-X. Epub 2017 Apr 26.

Reference Type: BACKGROUND

PMID: 28456501 (View on PubMed)

Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, Grant BF. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018 Apr 1;75(4):336-346. doi: 10.1001/jamapsychiatry.2017.4602.

Reference Type: BACKGROUND

PMID: 29450462 (View on PubMed)

Hall W, Saunders JB, Babor TF, Aasland OG, Amundsen A, Hodgson R, Grant M. The structure and correlates of alcohol dependence: WHO collaborative project on the early detection of persons with harmful alcohol consumption--III. Addiction. 1993 Dec;88(12):1627-36. doi: 10.1111/j.1360-0443.1993.tb02037.x.

Reference Type: BACKGROUND

PMID: 7907509 (View on PubMed)

Grant S, Azhar G, Han E, Booth M, Motala A, Larkin J, Hempel S. Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis. PLoS Med. 2021 Oct 8;18(10):e1003822. doi: 10.1371/journal.pmed.1003822. eCollection 2021 Oct.

Reference Type: BACKGROUND

PMID: 34624018 (View on PubMed)

Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, Hasin DS. Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015 Aug;72(8):757-66. doi: 10.1001/jamapsychiatry.2015.0584.

Reference Type: BACKGROUND

PMID: 26039070 (View on PubMed)

Grabski M, McAndrew A, Lawn W, Marsh B, Raymen L, Stevens T, Hardy L, Warren F, Bloomfield M, Borissova A, Maschauer E, Broomby R, Price R, Coathup R, Gilhooly D, Palmer E, Gordon-Williams R, Hill R, Harris J, Mollaahmetoglu OM, Curran HV, Brandner B, Lingford-Hughes A, Morgan CJA. Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder. Am J Psychiatry. 2022 Feb;179(2):152-162. doi: 10.1176/appi.ajp.2021.21030277. Epub 2022 Jan 11.

Reference Type: BACKGROUND

PMID: 35012326 (View on PubMed)

Feng YS, Kohlmann T, Janssen MF, Buchholz I. Psychometric properties of the EQ-5D-5L: a systematic review of the literature. Qual Life Res. 2021 Mar;30(3):647-673. doi: 10.1007/s11136-020-02688-y. Epub 2020 Dec 7.

Reference Type: BACKGROUND

PMID: 33284428 (View on PubMed)

Felton JW, Strutz KL, McCauley HL, Poland CA, Barnhart KJ, Lejuez CW. Delay Discounting Interacts with Distress Tolerance to Predict Depression and Alcohol Use Disorders among Individuals Receiving Inpatient Substance Use Services. Int J Ment Health Addict. 2020 Oct;18(5):1416-1421. doi: 10.1007/s11469-019-00163-5. Epub 2019 Nov 14.

Reference Type: BACKGROUND

PMID: 33312085 (View on PubMed)

Espinoza RT, Kellner CH. Electroconvulsive Therapy. N Engl J Med. 2022 Feb 17;386(7):667-672. doi: 10.1056/NEJMra2034954. No abstract available.

Reference Type: BACKGROUND

PMID: 35172057 (View on PubMed)

DiClemente CC, Carbonari JP, Montgomery RP, Hughes SO. The Alcohol Abstinence Self-Efficacy scale. J Stud Alcohol. 1994 Mar;55(2):141-8. doi: 10.15288/jsa.1994.55.141.

Reference Type: BACKGROUND

PMID: 8189734 (View on PubMed)

Devlin N, Pickard S, Busschbach J. The Development of the EQ-5D-5L and its Value Sets. In: Devlin N, Roudijk B, Ludwig K, editors. Value Sets for EQ-5D-5L: A Compendium, Comparative Review & User Guide. Cham (CH): Springer Copyright 2022, The Author(s). 2022. p. 1-12.

Reference Type: BACKGROUND

de Jonghe F, Kool S, van Aalst G, Dekker J, Peen J. Combining psychotherapy and antidepressants in the treatment of depression. J Affect Disord. 2001 May;64(2-3):217-29. doi: 10.1016/s0165-0327(00)00259-7.

Reference Type: BACKGROUND

PMID: 11313088 (View on PubMed)

Davis AK, Barrett FS, Griffiths RR. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Contextual Behav Sci. 2020 Jan;15:39-45. doi: 10.1016/j.jcbs.2019.11.004. Epub 2019 Nov 16.

Reference Type: BACKGROUND

PMID: 32864325 (View on PubMed)

Davidson J, Turnbull CD, Strickland R, Miller R, Graves K. The Montgomery-Asberg Depression Scale: reliability and validity. Acta Psychiatr Scand. 1986 May;73(5):544-8. doi: 10.1111/j.1600-0447.1986.tb02723.x.

Reference Type: BACKGROUND

PMID: 3751660 (View on PubMed)

Das RK, Gale G, Walsh K, Hennessy VE, Iskandar G, Mordecai LA, Brandner B, Kindt M, Curran HV, Kamboj SK. Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories. Nat Commun. 2019 Nov 26;10(1):5187. doi: 10.1038/s41467-019-13162-w.

Reference Type: BACKGROUND

PMID: 31772157 (View on PubMed)

Dakwar E, Levin F, Hart CL, Basaraba C, Choi J, Pavlicova M, Nunes EV. A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. Am J Psychiatry. 2020 Feb 1;177(2):125-133. doi: 10.1176/appi.ajp.2019.19070684. Epub 2019 Dec 2.

Reference Type: BACKGROUND

PMID: 31786934 (View on PubMed)

Craighead WE, Dunlop BW. Combination psychotherapy and antidepressant medication treatment for depression: for whom, when, and how. Annu Rev Psychol. 2014;65:267-300. doi: 10.1146/annurev.psych.121208.131653. Epub 2013 Sep 13.

Reference Type: BACKGROUND

PMID: 24405361 (View on PubMed)

Conigrave KM, Hall WD, Saunders JB. The AUDIT questionnaire: choosing a cut-off score. Alcohol Use Disorder Identification Test. Addiction. 1995 Oct;90(10):1349-56. doi: 10.1046/j.1360-0443.1995.901013496.x.

Reference Type: BACKGROUND

PMID: 8616463 (View on PubMed)

Close JB, Hajien EC, Watts R, Roseman L, Carhart-Harris RL. Psychedelics and psychological flexibility - Results of a prospective web-survey using the Acceptance and Action Questionnaire II. Journal of Contextual Behavioral Science. 2020;16:37-44.

Reference Type: BACKGROUND

Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders. Lancet. 2019 Aug 31;394(10200):781-792. doi: 10.1016/S0140-6736(19)31775-1.

Reference Type: BACKGROUND

PMID: 31478502 (View on PubMed)

Bschor T, Kern H, Henssler J, Baethge C. Switching the Antidepressant After Nonresponse in Adults With Major Depression: A Systematic Literature Search and Meta-Analysis. J Clin Psychiatry. 2018 Jan/Feb;79(1):16r10749. doi: 10.4088/JCP.16r10749.

Reference Type: BACKGROUND

PMID: 27929611 (View on PubMed)

Brenner P, Brandt L, Li G, DiBernardo A, Boden R, Reutfors J. Substance use disorders and risk for treatment resistant depression: a population-based, nested case-control study. Addiction. 2020 Apr;115(4):768-777. doi: 10.1111/add.14866. Epub 2019 Dec 16.

Reference Type: BACKGROUND

PMID: 31656053 (View on PubMed)

Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995 Jul;56(4):423-32. doi: 10.15288/jsa.1995.56.423.

Reference Type: BACKGROUND

PMID: 7674678 (View on PubMed)

Bilbao A, Martin-Fernandez J, Garcia-Perez L, Mendezona JI, Arrasate M, Candela R, Acosta FJ, Estebanez S, Retolaza A. Psychometric properties of the EQ-5D-5L in patients with major depression: factor analysis and Rasch analysis. J Ment Health. 2022 Aug;31(4):506-516. doi: 10.1080/09638237.2021.1875422. Epub 2021 Feb 1.

Reference Type: BACKGROUND

PMID: 33522336 (View on PubMed)

Bernstein EY, Baggett TP, Trivedi S, Herzig SJ, Anderson TS. Pharmacologic Treatment Initiation Among Medicare Beneficiaries Hospitalized With Alcohol Use Disorder. Ann Intern Med. 2023 Aug;176(8):1137-1139. doi: 10.7326/M23-0641. Epub 2023 Jun 27. No abstract available.

Reference Type: BACKGROUND

PMID: 37364264 (View on PubMed)

Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996 Dec;67(3):588-97. doi: 10.1207/s15327752jpa6703_13.

Reference Type: BACKGROUND

PMID: 8991972 (View on PubMed)

Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979 Apr;47(2):343-52. doi: 10.1037//0022-006x.47.2.343. No abstract available.

Reference Type: BACKGROUND

PMID: 469082 (View on PubMed)

Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using self-report assessment methods to explore facets of mindfulness. Assessment. 2006 Mar;13(1):27-45. doi: 10.1177/1073191105283504.

Reference Type: BACKGROUND

PMID: 16443717 (View on PubMed)

Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, Malone DA, Nikayin S, Nissen SE, Ostroff RB, Reti IM, Wilkinson ST, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023 Jun 22;388(25):2315-2325. doi: 10.1056/NEJMoa2302399. Epub 2023 May 24.

Reference Type: BACKGROUND

PMID: 37224232 (View on PubMed)

Alsheikh AM, Elemam MO, El-Bahnasawi M. Treatment of Depression With Alcohol and Substance Dependence: A Systematic Review. Cureus. 2020 Oct 26;12(10):e11168. doi: 10.7759/cureus.11168.

Reference Type: BACKGROUND

PMID: 33133799 (View on PubMed)

Alnefeesi Y, Chen-Li D, Krane E, Jawad MY, Rodrigues NB, Ceban F, Di Vincenzo JD, Meshkat S, Ho RCM, Gill H, Teopiz KM, Cao B, Lee Y, McIntyre RS, Rosenblat JD. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. J Psychiatr Res. 2022 Jul;151:693-709. doi: 10.1016/j.jpsychires.2022.04.037. Epub 2022 May 25.

Reference Type: BACKGROUND

PMID: 35688035 (View on PubMed)

Allen JP, Litten RZ, Fertig JB, Babor T. A review of research on the Alcohol Use Disorders Identification Test (AUDIT). Alcohol Clin Exp Res. 1997 Jun;21(4):613-9.

Reference Type: BACKGROUND

PMID: 9194913 (View on PubMed)

Other Identifiers

2025-12519

Identifier Type: -

Identifier Source: org_study_id